Renaissance Technologies (RenTech)'s ATYR Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 165,222 shares of aTyr Pharma, Inc. (ATYR) worth $98,604, representing 0.00% of the portfolio. First purchased in 2019-Q3, this long-term strategic position has been held for 27 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in ATYR, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2024, adding 394,883 shares. Largest reduction occurred in Q4 2024, reducing 574,720 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s aTyr Pharma (ATYR) Holding Value Over Time
Track share changes against reported price movement
Quarterly aTyr Pharma (ATYR) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +124,700 | Add 307.73% | 165,222 | $0.60 |
| Q1 2026 | +40,522 | New Buy | 40,522 | $0.78 |
| Q3 2025 | -518,355 | Sold Out | 0 | $0.00 |
| Q2 2025 | +38,400 | Add 8.00% | 518,355 | $5.07 |
| Q1 2025 | -94,500 | Reduce 16.45% | 479,955 | $3.02 |
| Q4 2024 | -574,720 | Reduce 50.01% | 574,455 | $3.62 |
| Q3 2024 | -144,639 | Reduce 11.18% | 1.15 M | $1.76 |
| Q2 2024 | +20,959 | Add 1.65% | 1.29 M | $1.56 |
| Q1 2024 | +394,883 | Add 44.98% | 1.27 M | $1.95 |
| Q4 2023 | +371,979 | Add 73.51% | 877,972 | $1.41 |
| Q3 2023 | -20,362 | Reduce 3.87% | 505,993 | $1.58 |
| Q2 2023 | +368,700 | Add 233.87% | 526,355 | $0.00 |
| Q1 2023 | -8,421 | Reduce 5.07% | 157,655 | $0.00 |
| Q4 2022 | -21,449 | Reduce 11.44% | 166,076 | $0.00 |
| Q3 2022 | +36,700 | Add 24.33% | 187,525 | $3.00 |
| Q2 2022 | +39,970 | Add 36.06% | 150,825 | $2.83 |
| Q1 2022 | -16,300 | Reduce 12.82% | 110,855 | $5.35 |
| Q4 2021 | -52,500 | Reduce 29.22% | 127,155 | $7.47 |
| Q3 2021 | +3,400 | Add 1.93% | 179,655 | $9.08 |
| Q2 2021 | -65,705 | Reduce 27.16% | 176,255 | $4.88 |
| Q1 2021 | -77,170 | Reduce 24.18% | 241,960 | $4.45 |
| Q4 2020 | -89,300 | Reduce 21.86% | 319,130 | $3.88 |
| Q3 2020 | +42,600 | Add 11.64% | 408,430 | $3.23 |
| Q2 2020 | +156,830 | Add 75.04% | 365,830 | $4.44 |
| Q1 2020 | +9,080 | Add 4.54% | 209,000 | $2.80 |
| Q4 2019 | +6,300 | Add 3.25% | 199,920 | $4.17 |
| Q3 2019 | +193,620 | New Buy | 193,620 | $3.50 |
Renaissance Technologies (RenTech)'s aTyr Pharma Investment FAQs
Renaissance Technologies (RenTech) first purchased aTyr Pharma, Inc. (ATYR) in Q3 2019, acquiring 193,620 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held aTyr Pharma, Inc. (ATYR) for 27 quarters since Q3 2019.
Renaissance Technologies (RenTech)'s largest addition to aTyr Pharma, Inc. (ATYR) was in Q1 2024, adding 1,272,855 shares worth $2.48 M.
According to the latest 13F filing for Q2 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 165,222 shares of aTyr Pharma, Inc. (ATYR), valued at approximately $98,604.
As of the Q2 2026 filing, aTyr Pharma, Inc. (ATYR) represents approximately 0.00% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in aTyr Pharma, Inc. (ATYR) was 1,293,814 shares, as reported at the end of Q2 2024.